Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Mild Cognitive Impairment-Pipeline Review, H1 2015

Mild Cognitive Impairment-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Mild Cognitive Impairment-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Mild Cognitive Impairment-Pipeline Review, H1 2015', provides an overview of the Mild Cognitive Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Mild Cognitive Impairment and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Mild Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Mild Cognitive Impairment Overview 9

Therapeutics Development 10

Pipeline Products for Mild Cognitive Impairment-Overview 10

Pipeline Products for Mild Cognitive Impairment-Comparative Analysis 11

Mild Cognitive Impairment-Therapeutics under Development by Companies 12

Mild Cognitive Impairment-Therapeutics under Investigation by Universities/Institutes 13

Mild Cognitive Impairment-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Mild Cognitive Impairment-Products under Development by Companies 16

Mild Cognitive Impairment-Products under Investigation by Universities/Institutes 18

Mild Cognitive Impairment-Companies Involved in Therapeutics Development 19

Actinogen Limited 19

Avraham Pharmaceuticals Ltd. 20

Boehringer Ingelheim GmbH 21

D-Pharm Ltd. 22

Eisai Co., Ltd. 23

Eli Lilly and Company 24

FORUM Pharmaceuticals Inc. 25

Octapharma AG 26

Sage Therapeutics 27

Sanofi 28

Suven Life Sciences Ltd. 29

Mild Cognitive Impairment-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

BAN-2401-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BCA-909-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CSP-1103-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

DAOI-B-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DP-NDD-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

FRM-0962-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

immune globulin (human)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ladostigil tartrate-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

levetiracetam-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

LY-3002813-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Peptide T-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

SAGE-547-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

SAR-228810-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

SUVN-501-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

SUVN-502-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

SUVN-507-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

SUVN-512-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

SUVN-976-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

SUVND-4010-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

tropisetron hydrochloride-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

UE-2343-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Mild Cognitive Impairment-Recent Pipeline Updates 69

Mild Cognitive Impairment-Dormant Projects 80

Mild Cognitive Impairment-Discontinued Products 82

Mild Cognitive Impairment-Product Development Milestones 83

Featured News & Press Releases 83

Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 83

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 83

May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 84

Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria. 85

Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 86

Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 86

Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland 87

Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer'S Disease 87

Aug 04, 2008: Suven Life Sciences Presents Positive Preclinical Data For Suvn-502 At Alzheimer'S Conference, Chicago And Drug Discovery Conference, Boston 88

Jul 07, 2008: Suven Life Sciences' Clinical Candidate Suvn-502 Being Presented At International Conference On Alzheimer'S Disease, ICAD-2008 At Chicago, USA 89

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2015 10

Number of Products under Development for Mild Cognitive Impairment-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Products under Investigation by Universities/Institutes, H1 2015 18

Mild Cognitive Impairment-Pipeline by Actinogen Limited, H1 2015 19

Mild Cognitive Impairment-Pipeline by Avraham Pharmaceuticals Ltd., H1 2015 20

Mild Cognitive Impairment-Pipeline by Boehringer Ingelheim GmbH, H1 2015 21

Mild Cognitive Impairment-Pipeline by D-Pharm Ltd., H1 2015 22

Mild Cognitive Impairment-Pipeline by Eisai Co., Ltd., H1 2015 23

Mild Cognitive Impairment-Pipeline by Eli Lilly and Company, H1 2015 24

Mild Cognitive Impairment-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 25

Mild Cognitive Impairment-Pipeline by Octapharma AG, H1 2015 26

Mild Cognitive Impairment-Pipeline by Sage Therapeutics, H1 2015 27

Mild Cognitive Impairment-Pipeline by Sanofi, H1 2015 28

Mild Cognitive Impairment-Pipeline by Suven Life Sciences Ltd., H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Mild Cognitive Impairment Therapeutics-Recent Pipeline Updates, H1 2015 69

Mild Cognitive Impairment-Dormant Projects, H1 2015 80

Mild Cognitive Impairment-Dormant Projects (Contd..1), H1 2015 81

Mild Cognitive Impairment-Discontinued Products, H1 2015 82

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H1 2015 10

Number of Products under Development for Mild Cognitive Impairment-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actinogen Limited

Avraham Pharmaceuticals Ltd.

Boehringer Ingelheim GmbH

D-Pharm Ltd.

Eisai Co., Ltd.

Eli Lilly and Company

FORUM Pharmaceuticals Inc.

Octapharma AG

Sage Therapeutics

Sanofi

Suven Life Sciences Ltd.

Mild Cognitive Impairment Therapeutic Products under Development, Key Players in Mild Cognitive Impairment Therapeutics, Mild Cognitive Impairment Pipeline Overview, Mild Cognitive Impairment Pipeline, Mild Cognitive Impairment Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com